Anebulo Pharmaceuticals Inc (ANEB) - Total Liabilities
Based on the latest financial reports, Anebulo Pharmaceuticals Inc (ANEB) has total liabilities worth $1.49 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anebulo Pharmaceuticals Inc - Total Liabilities Trend (2020–2025)
This chart illustrates how Anebulo Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See ANEB working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Anebulo Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Anebulo Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trivarx Ltd
AU:TRI
|
Australia | AU$771.99K |
|
Assura PLC
LSE:AGR
|
UK | GBX1.64 Billion |
|
Kabelindo Murni Tbk
JK:KBLM
|
Indonesia | Rp330.17 Billion |
|
Ulima Nitra PT
JK:UNIQ
|
Indonesia | Rp272.93 Billion |
|
Puma Exploration Inc
V:PUMA
|
Canada | CA$1.38 Million |
|
North Eastern Carrying Corporation Limited
NSE:NECCLTD
|
India | Rs1.45 Billion |
|
Han Express
KO:014130
|
Korea | ₩315.01 Billion |
|
Kamdhenu Ventures Limited
NSE:KAMOPAINTS
|
India | Rs1.11 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Anebulo Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ANEB market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anebulo Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anebulo Pharmaceuticals Inc (2020–2025)
The table below shows the annual total liabilities of Anebulo Pharmaceuticals Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $487.69K | +87.15% |
| 2024-06-30 | $260.58K | -75.62% |
| 2023-06-30 | $1.07 Million | +108.53% |
| 2022-06-30 | $512.53K | +112.11% |
| 2021-06-30 | $241.63K | +7.94% |
| 2020-06-30 | $223.87K | -- |
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more